Skip to content

Advertisement

Open Access

Comparison of antimicrobial resistance rates in an ICU in Rio de Janeiro, Brazil and the United States

  • MS Santos1,
  • FL Gutierrez1,
  • JLF Costa1,
  • PN Gomes1 and
  • RC Costa-Filho1
Critical Care20059(Suppl 2):P72

https://doi.org/10.1186/cc3616

Published: 9 June 2005

Keywords

Minimum Inhibitory ConcentrationEmergency MedicineInhibitory ConcentrationTesting StandardLaboratory Standard

Introduction

Antimicrobial resistance has been the major problem for treating patients in the ICU. Most international guidelines are based on antimicrobial resistance rates observed in the USA. For an empirical antimicrobial decision strategy it is important to know the differences between local and imported data.

Objective

To compare local ICU antimicrobial resistance rates (RJ-ICU) with USA-ICU antimicrobial resistance rates (USA-ICU).

Methods

A prospective analysis of antimicrobial resistance rates in a seven-bed medical–surgical ICU in Rio de Janeiro, Brazil and comparison with ICARE (CDC-USA) rates. All isolates were responsible for hospital-acquired infections. The National Committee for Clinical Laboratory Standards were used for the minimum inhibitory concentration, or zone diameter testing standards reporting susceptible, intermediate, or resistant organisms.

Results

The rates of antimicrobial resistance were: methicillin-resistant S. aureus, 50% RJ-ICU vs 68% USA-ICU (P = 0.165); quinolone-resistant P. aeruginosa, 80% RJ-ICU vs 52% USA-ICU (P < 0.0001); imipenem-resistant P. aeruginosa, 49% RJ-ICU vs 38% USA-ICU; ceftazidime-resistant P. aeruginosa, 32% RJ-ICU vs 24% USA-ICU (P = 0.15); third cephalosporin-resistant Enterobacter spp., 60% RJ-ICU vs 47% USA-ICU (P = 0.412); and third cephalosporin-resistant K. pneumoniae, 30% RJ-ICU vs 21% EUA-ICU (P = 0.329).
Figure 1

Figure 1

Conclusion

Quinolone-resistant P. aeruginosa was significantly higher in the RJ-ICU than in the USA-ICU. We speculate that this difference could be related to different antimicrobial use or patient severity.

Authors’ Affiliations

(1)
Nugesco – Núcleo Gestor do Conhecimento em Terapia Intensiva, Hospital Pró-Cardíaco, Rio de Janeiro, Brazil

Copyright

© BioMed Central Ltd 2005

Advertisement